← All trials
NCT05231590
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 23, 2022
- Primary completion
- Apr 14, 2022
- Completion date
- Sep 30, 2022
- First posted
- Feb 9, 2022
- Last posted
- Oct 17, 2022
- Enrollment
- 581
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- CinnagenLead sponsor
- Vaxine Pty LtdCollaborator
- Shahid Beheshti University of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.